FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Opinion On Shares Of Builders Firstsource, Inc.

作者

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month price target to $85 from $125, based on a 2027 P/E of 13.1x, a premium to the stock's 10-year average forward P/E of 12.1x, justified by cyclical trough market conditions. We lower our adjusted EPS estimates to $4.10 from $6.69 for 2026 and to $6.50 from $8.01 for 2027. BLDR posted Q1 2026 adjusted EPS of $0.27 vs. $1.51 (-82% Y/Y), well short of the $0.37 consensus. BLDR's Q1 sales fell 11% to $3.29B ($130M ahead of consensus), but gross margin contracted 220 bps to 28.3%. BLDR said it now expects 2026 net sales of $14.6B-$15.6B and adjusted EBITDA of $1.1B-$1.5B, versus prior expectations of $14.8B-$15.8B and $1.3B-$1.7B, respectively. Management said it remains focused on factors within its control, including serving customers, expanding its differentiated portfolio of value-added solutions, and leveraging technology to accelerate growth and drive operational excellence. We think BLDR's Q1 results underscore challenges the company faces from a weaker housing market.

相關文章

Asia

Telix Pharmaceuticals公司的在開發顯影劑或可用於診斷多種腎癌

Telix Pharmaceuticals(ASX:TLX)週二表示,其在開發顯影劑TLX250-Px有望用於診斷除透明細胞腎細胞癌(ccRCC)以外的其他腎癌。該公司援引發表在《歐洲泌尿外科雜誌》(European Urology)上的一項獨立分析稱,該分析顯示,TLX250-Px的三期臨床試驗數據表明,PET掃描陽性結果對惡性腫瘤具有“高度預測性”,包括非透明細胞腎細胞癌,其陽性預測值高達98%。 Telix集團首席醫療官David Cade表示:“ZIRCON研究中幾乎所有ccRCC假陽性結果均已被證實為其他惡性腎癌亞型,這降低了過度治療的風險,並進一步支持了該藥物的臨床應用。”

$ASX:TLX
Asia

華錦國際董事長、執行長面臨消費限制令

華錦國際(HKG:2738)週二在香港交易所發佈公告稱,其董事長徐松慶和首席執行官陳春牛因涉嫌拖欠款項而被下達消費限制令。 該公司董事長徐松慶和執行長陳春牛的消費限制令已於11月25日生效。 該案源自於該公司旗下兩家子公司江門華木金屬有限公司及江門華錦金屬製品有限公司涉嫌拖欠1.3億元人民幣的融資租賃款項。截至4月30日,仍有1,640萬元人民幣未支付給債權人。 徐松慶和陳春牛一直在與債權人協商解決此事,公司預計在8月底前達成和解。

$HKG:2738
Asia

塔塔化工第四財季綜合虧損擴大

塔塔化工(NSE:TATACHEM,BOM:500770)截至3月31日的第四財季,合併歸屬於股東的虧損擴大至213億印度盧比,去年同期虧損為15.6億盧比。 這家化學製造商週一向印度證券交易所提交的文件顯示,每股虧損增加至83.68盧比,去年同期每股虧損為2.19盧比。 第四財季營業收入從去年同期的351億盧比降至344億盧比,低於Visible Alpha調查的分析師先前預測的348億盧比。 公司董事會建議派發截至3月31日財年的每股11盧比的股利。

$BOM:500770$NSE:TATACHEM